Curis Q4 2020 Earnings Report
Key Takeaways
Curis, Inc. reported a net loss of $7.5 million, or $0.11 per share, for Q4 2020. Revenues for the quarter were $3.0 million. The company's cash, cash equivalents, and investments totaled $183.1 million as of December 31, 2020, expected to fund operations into 2024.
Significantly expanded IRAK4 inhibitor CA-4948 development, including new clinical trials and a CRADA with the NCI.
Presented CA-4948 Phase 1 data showing broad clinical activity in patients with R/R AML/MDS and R/R NHL.
Raised $169.6M in a December 2020 public offering, extending cash runway into 2024.
Multiple data readouts expected in 2021 from CA-4948 and anti-VISTA antibody CI-8993 clinical trials.
Curis
Curis
Curis Revenue by Segment
Forward Guidance
Curis anticipates several milestones in 2021, including reporting additional clinical data from ongoing trials and announcing initial safety and efficacy data from combination studies.
Positive Outlook
- Report additional clinical data from the Phase 1 study of CA-4948 in patients with AML and high-risk MDS in mid-year 2021.
- Report additional clinical biomarker data gathered in the Phase 1 study of CA-4948 in patients with R/R NHL in mid-year 2021.
- Announce initial safety and efficacy data from the ongoing Phase 1 study of CA-4948 in combination with ibrutinib in patients with R/R NHL in the second half of 2021.
- Report initial safety and efficacy data from the ongoing Phase 1a/1b dose-escalation study of CI-8993 for the treatment of R/R solid tumors in the second half of 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income